Moderna announces first participant dosed in phase 3 study of mrna-1083, a combination vaccine against influenza and covid-19
Mrna-1083 is moderna's first respiratory combination vaccine candidate to enter a phase 3 trial phase 3 initiation follows data from a phase 1/2 trial where mrna-1083 showed strong immunogenicity against influenza and covid-19, with an acceptable reactogenicity and safety profile, compared to licensed standalone vaccines company has multiple programs in phase 3 development across several areas, including respiratory diseases, latent viruses, and oncology cambridge, ma / accesswire / october 24, 2023 / moderna, inc. (nasdaq:mrna) today announced that the first participant has been dosed in a phase 3 study of the company's combination vaccine candidate against influenza and covid-19 (mrna-1083) in the u.s. the trial is expected to enroll approximately 8,000 adults in the northern hemisphere. the phase 3 study will evaluate the immunogenicity, safety, and reactogenicity of mrna‐1083 as compared with active control, co‐administered licensed influenza and sar‐cov‐2 vaccines in two independent age‐group sub‐study cohorts involving 4,000 adults 65 years and older and 4,000 adults 50 to
MRNA Ratings Summary
MRNA Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission